The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global gastroparesis drugs market reached a value of US$ 5.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.8 Billion by 2027, exhibiting at a CAGR of 5.15% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Gastroparesis, also known as stomach paralysis, is a medical condition that affects the normal and spontaneous movement of the muscles in the stomach. It interferes with the digestion process and causes nausea, vomiting, abdominal pain, and problems with maintaining blood sugar levels and nutrition absorption. At present, it is treated under the guidance of doctors using drugs, such as domperidone, metoclopramide, erythromycin, diphenhydramine, ondansetron, and prochlorperazine.
Due to rapid urbanization, sedentary lifestyles and the growing number of individuals who drink and smoke regularly, there is a significant rise in the prevalence of diabetes across the globe. This, in confluence with the increasing geriatric population, which is relatively more susceptible to developing gastroparesis, represents one of the key factors bolstering the growth of the market. In addition, gastroparesis drugs aid in enhancing gastrointestinal motility by improving the frequency of contraction. As a result, they are extensively being utilized for treating idiopathic gastroparesis, which causes severe vomiting, nausea, and upper abdominal pain. This, along with a considerable rise in the number of individuals developing gastroparesis after the vague nerve and its branches are damaged via surgical operations, are also contributing to market growth. Furthermore, leading manufacturers are continuously funding research and development (R&D) projects to introduce new approaches to the existing drug therapy. They are also developing advanced and effective drugs that can be administered via the nasal cavity for individuals who are experiencing symptoms of gastroparesis, which is creating a favorable market outlook. Other major factors, including the improving healthcare infrastructure and the escalating demand for user-friendly drugs, are anticipated to impel the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global gastroparesis drugs market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on disease type, drug class and distribution channel.
Breakup by Disease Type:
Breakup by Drug Class:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Theravance Biopharma.
|Base Year of the Analysis||2021|
|Segment Coverage||Disease Type, Drug Class, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Theravance Biopharma|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at